US FDA extends review of Exelixis' cancer drug - reuters.com
US FDA extends review of Exelixis' cancer drug reuters.com
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNNlRFbVVQQ0VQR0kwemFaVlBqNnR5akttN2dMeGRncGlOS1VIemxmeHdSTklYTk81VF9XQUtTSlhURXNXUEFxbER1eUxnT3B2UmRVV0I0a3pGVHFrZDRLWWpPTlk4enBfX0FkOGtES3U5cDRsWE9WZHpLQ0RNN1RUTGMwUGdPQW1YLWlKSFJ6NGs4elE2OGl3NGxKUQ?oc=5" target="_blank">US FDA extends review of Exelixis' cancer drug</a> <font color="#6f6f6f">reuters.com</font>
Similar Stories
Related coverage based on topic and tags
US FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMUS FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PM